Novo Nordisk has provided updates on its insulin and GLP-1 product lines. Following a previous announcement of price reductions, the company has discontinued the basal insulin Levemir.
Results for: Levemir
Novo Nordisk’s decision to discontinue Levemir insulin has sparked concerns among Democratic senators. Despite initial praise for Novo’s acquisition of up to 75% of the insulin market, the discontinuation has led to supply disruptions and insurance cutoffs, leaving patients with limited options.